Needham analyst Mike Matson reiterated a Hold rating on Globus Medical (NYSE: GMED).The analyst commented: 'GMED's 3Q25 revenue and EPS ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE